A B S T R A C T Sodium phenobarbital and various hormones, compounds capable of hepatic enzyme induction, were given to an infant boy with congenital, nonhemolytic, unconjugated, hyperbilirubinemia and severe kernicterus for prolonged periods between the ages of 2 and 25 months to determine their effect on serum bilirubin concentrations. Phenobarbital, 5 mg/day orally, on two occasions decreased serum bilirubin concentrations approximately threefold over a period of 30 days. Withdrawal of phenobarbital after the first study resulted in a gradual (30 days) return of serum bilirubin to pretreatment levels. The lower serum bilirubin concentrations observed when phenobarbital therapy was reinstituted were maintained for 61 days on 2.5 mg/kg per day of the drug. Orally administered L-triiodothyronine, 0.05-0.1 mg/day for 71 days, intramuscular human growth hormone, 1 mg/day for 21 days, and testosterone propionate, 0.1 mg/day for 9 days, did not decrease serum bilirubin levels below lowest control values of 18 mg/100 ml.
INTRODUCTION
In recent years, investigations in many animal species, including man, have shown that a variety of polycyclic hydrocarbons, insecticides, drugs, and hormones enhance the activities of microsomal and soluble enzymes and increase hepatic agranular endoplasmic reticulum (AER). Results of these investigations have been summarized by early workers in this field (1) (2) (3) (4) (5) (6) . The frequency of this pharmacological response is emphasized in a compilation by Conney (5) in 1965 which showed that stimulation of drug-metabolizing enzymes had been observed with over 100 drugs and other compounds.
Catz and Yaffe (7) and Arias, Gartner, Furman, and Wolfson (8) first demonstrated that the in vivo administration of various drugs and chemicals increased in vitro activity of the uridine diphosphate glucuronic acid transglucuronylase (UDPGA transferase) system for bilirubin in rats, rabbits, and mice. However, Arias et al. (8) , in exploring the potential use of these drugs to accelerate the formation of bilirubin glucosiduronate in man, showed that the administration of chloroquine to pregnant women, for 1-8 wk before delivery, was unable to alter the hyperbilirubinemia present in their newborn infants.
The ability of phenobarbital to stimulate the transformations of drugs (9) and steroid hormones in various animals (10) and man (11) and our current use of this drug in studies of steroid hormone metabolism led us to investigate the effect of phenobarbital on the bilirubin metabolism of an infant with marked congenital, nonhemolytic, unconjugated hyperbilirubinemia, who had suffered severe, irreversible neurological damage during the 1st month of life. This paper reports changes observed in serum bilirubin concentrations and in the kinetics of bilirubin turnover before and during phenobarbital administration to this infant (12, 13) . Coincident with these studies, Yaffe, Levy, Matsuzawa, and Baliah (14) described a similar effect of phenobarbital on serum bilirubin concentrations in an infant with congenital nonhemolytic jaundice and reported a drug-induced increase in the capacity to conjugate salicylamide as glucosiduronate.
METHODS
Clinical course and study periods. T. U. was hospitalized from 2 to 23 months of age and for 2 wk at 25 months of age. He was the seventh child of a 42 yr old gravida 7, para 7 woman. One day of bleeding occurred in the 2nd month of pregnancy. At 7 months, premature rupture of membranes was accompanied by a febrile illness of unknown cause which responded to antibiotics. Birth weight was 2.06 kg. Jaundice during the 1st wk of life was thought to be physiological. However, when he was seen at 2 months of age because of an umbilical hernia, marked jaundice was present.
The patient's maternal grandmother had intermittent, indirect hyperbilirubinemia (serum bilirubin, 1.7 mg/100 ml). She had been studied at another hospital, and no evidence of hemolysis or liver disease had been found. The patient's oldest brother had been jaundiced in the newborn period.
At 2 months of age, T. U. was 135 cm in length and weighed 4.38 kg. His skin was orange-yellow in color, and he had marked clinical evidence of kernicterus. There was a small umbilical hernia. The liver and spleen were not enlarged.
Initial laboratory studies were as follows: hemoglobin 12.7 g/100 ml, hematocrit 39.5%o, reticulocytes 1.0%, and WBC 7000/mm3 with a normal differential. Urinalysis was normal and was negative for bilirubin (Ictotest, Ames Co., Inc., Elkhart, Ind.) and urobilinogen (15) . Serum bilirubin (16) was usually between 17 and 25 mg/100 ml, virtually all indirect reacting. Values from 35 to 39 mg/100 ml were observed after an exchange transfusion 7 days before his first admission and after surgery for liver biopsies ( Schmid and Hammaker (21) .
Preparation of bilirubin-3H and bilirubin-`C. Crystalline bilirubin was treated with tritium gas according to the procedure of Wilzbach (22) . The crude product was washed with methanol and the methanol removed by evaporation. The residue was crystallized several times from hot pyridine (23) . After addition of unlabled bilirubin, the preparaadaptation of the methods of Kingsley (17) and Gornall, Bardawill, and David (18) and protein electrophoresis carried out on a Beckman Model R paper electrophoresis system by procedure B described in the Instruction Manual (November, 1957) . The Quick prothrombin time was done using the test procedure described by Hyland Division Travenol Laboratories, Inc., Los Angeles, Calif., who prepared the thromboplastin. Serum glutamic oxalacetic transaminase (SGOT), glutamic pyruvic transaminase (SGPT), and lactic dehydrogenase (LDH) were determined using reagent tubes (Determatubes) prepared by the Worthington Biochemical Corp., Freehold, N. J., with slight modifications.
Normal values in units per milliliter for infants are for SGOT, 10-60 for SGPT, and 40-100 for LDH. tion was dissolved in isopropanol: 0.5 N NaOH, 7: 3 v/v, and allowed to sit 10 min at room temperature in the dark. Bilirubin, precipitated by lowering the pH to 2 with 6 N HCL. was extracted with chloroform. The chloroform was washed with water and removed by evaporation. From the residue, bilirubin-2H, 1 .75 X 106 dpm/mg, was obtained by two crystallizations from hot pyridine. Its specific activity was not altered by further treatment with alkali and acid.
The molar extinction coefficient of the bilirubin-'H preparation was 5960 in chloroform (23) . Bilirubin-'4C, 12.2 X 106 dpm/mg, prepared from 8-aminolevulinic acid-14C according to Ostrow, Hammaker, and Schmid (24) , was supplied by Dr. Stephen Robinson. Dried, labeled bilirubin preparations, stored in the dark at room temperature until ready for use, retained their original specific activities.
Intravenous administration of bilirubin solutions. All intravenous solutions were prepared immediately before administration and injected in 1 min into the right external jugular vein. Control 1: 3.5 mg of bilirubin-'H was placed in a sterile vial and dissolved in 3 ml of a pH 11 solvent (0.067 M phosphate buffer adjusted to pH with N NaOH). 20 ml of sterile 0.067 M phosphate buffer, pH 7.4, was added, and 21.9 ml, equivalent to 3.33 mg of bilirubin, and 5.8 X 10' dpm of 'H were administered. Control 2: 3.3 mg of bilirubin-'H was dissolved in 3 ml of the pH 11 solvent.
In quick succession, 13.0 ml of the phosphate buffer and 4.0 ml of sterile 25% human serum albumin were added. 19 ml of this clear solution, equivalent to 3.15 mg of bilirubin and 5.5 X 10' dpm of 'H was administered. Phenobarbital study: 6.6 mg of bilirubin-'H and 0.158 mg of bilirubin-14C were dissolved in 4 ml of pH 11 solvent. 18 ml of sterile pH 7.4 phosphate buffer was then added, and 20.5 ml of this solution, equivalent to 6.4 mg of bilirubin, 11.0 X 10' dpm of 'H, and 1.83 X 10' dpm of 14C were administered.
Blood, stool, and urine collections. Approximately 2 ml of blood was drawn for serum at 2, 10, 20, 30, 45, and 60 min and at 2, 3, 4, 6, 8, and 12 hr after the administration of labeled bilirubin. Thereafter, samples were taken twice daily, at 8:00 a.m. and 4:00 p.m., until serum radioactivity was too low for quantitative determination. Stools were collected as 3-day pools in control 1, and individually in control 2 and phenobarbital studies with carmine markers used to estimate transit time. Continuous 24-hr urine collections were made. Serum, stools, and urines were kept frozen until analyzed. (26) . Backgrounds were 32 cpm for 'H alone, and 8 and 13 cpm in scalers A (14C) and C ('H), respectively, when both isotopes were counted simultaneously. Sample vials, backgrounds, and standards were prepared in duplicate and counted 10 times for 10 min each. Toluene-'H and toluene-'4C were used for internal quench corrections.
Crystallization of serum bilirubin. Unlabeled bilirubin was added to a pool of sera obtained from the bilirubin-'H and bilirubin-14C (phenobarbital) study and the bilirubin extracted from the pooled sera with the Weber and Schalm (25) reagent. A portion of extract was analyzed for radioactivity as previously described for measurement of serum specific activity. The extract which remained was washed with water, 10% NaCl, and water again, and the bilirubin which precipitated was crystallized once from methanol and once from chloroform-methanol. The Radioactivity in urines. 1 ml of urine was added to each of six vials containing 15 ml of scintillation fluid (84 ml of Liquifluor, 416 ml of toluene, and 500 ml of methyl Cellosolve). Internal standards of 'H20 were added to two vials and toluene-"C to another two to correct for quenching. 1 ml of H20 served as background. For 'H alone, background was 33 cpm, and the unquenched efficiency was 5%0.
For 1'C and 'H, measured simultaneously, backgrounds were 12 cpm, scaler A ("4C), and 25 cpm, scaler C ('H), with unquenched efficiencies of 25% and 4.5%, respectively.
Accumulation of counts was the same as described -for serum.
Mathematical analyses of kinetic data. The logarithm of the specific activity of serum bilirubin has been plotted as a function of time for each study. Exponentials 1 represent the best straight lines drawn by the method of least squares through the final, first-order portion of each curve. Successive subtractions of first-order plots (29) of the serum specific activity curves of both control and phenobarbital studies resulted in three first-order slopes, exponentials 1, 2, and 3. The subtractions for exponentials 2 and 3 were performed graphically. Each curve, therefore, is described by the general equation, v = aoe-it + a2e-'-t + a3e-s3t (29) , where iv is serum bilirubin specific activity at time, t, and a,, a2, and a3 the bilirubin specific activities at t = 0 of the respective slopes Xi, X2, and X3.
The slope, X1, and its intercept a1, which are considered to represent steady-state values after complete mixing, were used to calculate total body pool and turnover of bilirubin (29) . The additional exponentials of the general equation describe, at least, two other biological compartments of bilirubin which are distinguished readily by the marked differences in their rates of mixing (X2 and X3) with the plasma pool. A compartmental analysis of the data, however, is not attempted in this paper.
In vitro liver studies Electron microscopy. 1-mm cubes of liver obtained by biopsy before (age 551 days) and during (age 677 days) phenobarbital therapy were fixed either in 5% glutaraldehyde-sodium cacodylate buffer, followed by washing and further fixation in Dalton's chrome-osmium solution, or directly, in Dalton's chrome-osmium solution. Tissues were processed for electron microscopy as described by Uzman, Foley, Farber, and Lazarus (30) . 1-it sections of several blocks of each specimen were examined by phase microscopy and appropriate areas selected for thin sectioning and electron microscopic examination. Two types of analyses were done to establish whether or not phenobarbital treatment significantly altered the amount of AER in the hepatocyte population. First, several blocks of each specimen were cut and random electron micrographs taken and blind-sorted on the basis of the amount of AER present. Second, the amount of AER in hepatocytes adjacent to portal areas of the tissue obtained during phenobarbital therapy was compared to that of hepatocytes near the central part of the lobule of the specimen obtained before phenobarbital administration. The latter comparison was made as, perhaps, the most demanding test of the effect of phenobarbital on AER proliferation since Burger and Herdson (31) and Becker and Lane (32) nate alone and with T3 and phenobarbital, respectively, for shorter periods (Table I , periods 2-6, 9-10, and 12). These hormones failed to decrease serum bilirubin levels.
Effect of phenobarbital on serum bilirn bin concentration. The ability of sodium phenobarbital, 5 mg/kg per day, to reduce serum bilirubin concentration from approximately 20 mg/100 ml to levels of about 6 mg/100 ml at two ages, is shown in Fig. 1 rubin concentrations (Table I , periods 17 and 18). Withdrawal of phenobarbital (Fig. 2) , however, led to a gradual increase in serum bilirubin concentration until the pretreatment level was reestablished.' 4 In Fig. 2 , the bilirubin concentrations of 10.5 mg/100 ml, observed for approximately 30 days before discontinuing phenobarbital administration, and of 22-24 mg/100 ml, noted after phenobarbital withdrawal, are somewhat higher than those observed during the periods illustrated in Fig. 1 Serum bilirubin concentrations in Figs. 1 and 2 were plotted logarithmically as a function of time with best straight lines drawn by the method of least squares to obtain slopes characterizing the processes of change during phenobarbital administration and withdrawal. These plots serve only as a convenient means of mathematical description and are not meant to imply that the kinetics of this change are known to be first order. In patient resulting from a persistent, low-grade respiratory infection during the interval shown in Fig. 2 (Fig. 3) and for the phenobarbital study (Fig. 4) (Figs. 3A' and B' ) are similar. The early distribution and metabolism of bilirubin-3H therefore, appear to be the same whether the labeled bilirubin is injected in a buffered aqueous solution (control 1) or in 5% human serum albumin (control 2).
The turnover data for the control studies (Table II) showed, unexpectedly, that the higher serum concentration of unconjugated bilirubin in control 2, 23 mg/100 ml vs. 20 mg/100 ml, was associated with a significant decrease in bilirubin half-life, 84 hr vs. 111 hr, a slight decrease in total body bilirubin pool, 184 mg vs. 200 mg, and a moderate increase in bilirubin turnover, 37 mg/day vs. 30 mg/day. It is not possible to assign any significance to the apparent differences in the vascular and extravascular pools, expressed in Table II by the extravascular pool: vascular pool ratios. Variations between the two control studies are thought to be due to biological changes in the patient which resulted from infection that began during the first study and persisted, in spite of antibiotic therapy. throughout the second study (see Methods).
Phenobarbital therapy. The specific activity curves for bilirubin-3H and bilirubin-'4C plotted in Fig. 4 Fig. 3 . Equations (see Methods): y1 (3H) = 151e-o19t + 85eol165t + 151e-1 73t; y (14C) = 25e'-l"t + 4eO-1t + 25e-144t.
In addition, the 3H/'4C value of bilirubin crystallized from a pool of the sera was the same as that of the administered labeled bilirubins (see Methods).
The decreased mean serum bilirubin concentration, 6.7 mg/100 ml, during phenobarbital administration was accompanied by a comparable reduction in total bilirubin pool without a significant change in extravascular pool:vscular pool ratio or in bilirubin turnover (Table  II) Rate of excretion of radioactivity in urine compared with that in serum. Each point represents total radioactivity from bilirubin-3H excreted per 24 hr in urine during control 2 (0) and phenobarbital (0) studies. Data for control 1 were not obtained. Slopes of serum bilirubin specific activity curves are plotted to demonstrate how closely data approach those expected under steady-state conditions. in stool (Fig. 5 ) and 3H in urine (Fig. 6 ) during control and phenobarbital studies was similar to the rate of decrease of serum bilirubin specific activities in the respective studies, an observation consistent with steadystate conditions. Cumulative recovery of 'H and 14C from stool and urine for the three studies is shown in Table III . Most of the radioactivity, as expected, is found in stool with only 7% of the injected dose excreted in urine in times equivalent to 4 or more halflives of bilirubin. No explanation for the 48% recovery of total radioactivity in control 1 is evident since early values of serum specific activity exclude a significant error in measuring the injected dose, and no error in the analyses of the stool and urine radioactivity was detected. Effect of phenobarbital on liver structure. Examination of the liver biopsies obtained before and during phenobarbital administration by light microscopy, carried out by Dr. Gorden Vawter, showed no significant differences and no pathological abnormalities. Electron microscopy ( Fig. 7) performed by Dr. B. G. Uzman, however, revealed a marked increase in AER after phenobarbital administration, a drug-induced change in hepatic cells described in other animal species (6, 31, 32, 35, 36) but not previously documented in man.
The changes in AER content of hepatocytes were readily distinguished by blind-sorting of electron micrographs from specimens before vs. those during phenobarbital therapy and were clearly evident when cells from the portal area of the tissue removed during phenobarbital therapy were compared to centrally located hepatocytes of the pretreatment specimen ( Fig. 7 a and b vs. c and d). The latter analysis was based on studies in rats (31, 32) which showed that phenobarbital-induced increases of AER occurred more slowly and to a lesser extent in the portal area of the liver lobule.
Conjugation of PNP. The rate of conjugation of PNP, presumably as glucosiduronate (33) , was calculated from the zero-order kinetics of the first 30 min of incubation with all three liver homogenates (Fig. 8) (38) suggest that excess thyroid hormone augments glucosiduronate conjugation of steroid hormones in human beings, and neonatal hypothyroidism is known to be associated with increased unconjugated hyperbilirubinemia (39, 40) . Human growth hormone and testosterone propionate were given because testosterone and other anabolic steroids in some animals stimulate glucosiduronate formation (41) and augment the response of enzyme systems to drugs (41) (42) (43) . Serum bilirubin concentrations of the patient, however, were not decreased by human growth hormone or testosterone (Table I, periods 5, 6, and 12) .
The detailed data on bilirubin metabolism reported in this paper were obtained to elucidate independent observations originally described by us (11, 12) and by Yaffe et al. (14) of the ability of phenobarbital to markedly reduce serum bilirubin concentrations to two infants with congenital, nonhemolytic, unconjugated hyperbilirubinemia. Serum bilirubin concentrations in both infants decreased over a period of 3-4 wk to 3 and 7 mg/100 ml, values approximately one-third of those observed before phenobarbital was begun. and returned to pretreatment levels at a similar rate when the drug was discontinued. The fall in serum bilirubin concentration was associated with a significant decrease in clinical jaundice, suggesting either decreased bilirubin turnover, increased fractional turnover (decreased ti), or sequestration of bilirubin in a nonvisible compartment. The reduction in serum bilirubin concentration during phenobarbital therapy was not due to a decrease in the rate of bilirubin formation since this was normal in control studies and was not significantly affected by phenobarbital (Table II) .' Although there was a slight increase in the proportion of total body bilirubin in the extravascular pool during phenobarbital administration (Table II) , a finding which might reflect some alteration in the binding of bilirubin to plasma proteins (45, 46) , the major effect of phenobarbital was on bilirubin half-life which was decreased two-to threefold. Thus, phenobarbital increased the rate of removal of bilirubin from the body pool and, thereby, proportionally diminished the amounts of both vascular and extravascular bilirubin.
,.Seyeral Distinctive properties of the manner in which phenobarbital lowers the serum bilirubin concentration are evident. First, the approximately 30 days required to reach a new level of 5-7 mg of bilirubin per 100 ml of serum under phenobarbital treatment is several times longer than would be expected if the fractional turnover rate (Xi) determined during phenobarbital administration had been established soon after introduction of the drug (see Appendix II). The long interval required to reach the lower level of serum bilirubin concentration appears more consistent with an action of phenobarbital governed by a slow, rate-limiting step rather than by one involving only a rapid process such as a change in the binding constant of albumin to bilirubin (45, 46) . Second, the rate at which the serum bilirubin concentration increases after withdrawal of phenobarbital is essentially the same rate at which it falls after initiating therapy (Figs. 1 and 2 and Appendix I). 5 Schmid and Hammaker (22) , using bilirubin-'4C, have previously demonstrated a normal turnover of bilirubin in a 41 year old boy with congenital, nonhemolytic, hyperbilirubinemia. Since bilirubin turnover was essentially unaltered in our patient during phenobarbital treatment, it is assumed that any increase in bilirubin production from nonerythroid sources, claimed to occur in this patient during phenobarbital administration (44) , was small in comparison to the total bilirubin turnover. This suggests that the same, slow, rate-limiting step may also be the dominant factor in controlling the rate of increase in serum bilirubin concentration upon withdrawal of phenobarbital. Observations in Gunn rats and in patients with congenital nonhemolytic jaundice suggest that the elevated level of serum bilirubin is the result of a deficiency in the enzymatic system converting bilirubin to its readily excretable glucosiduronate (47) . These considerations, together with the findings that phenobarbital and similar drugs can stimulate or induce the in vivo formation of enzyme systems accelerating various aspects of the metabolism of drugs and hormones, including conjugation as glucosiduronate (9, 10, 41, 48, 49) , imply that the action of phenobarbital has been to induce the formation of a bilirubin-metabolizing enzyme system. Such a concept is supported by the findings of Yaffe et al. (14) that phenobarbital therapy was able to return a deficient glucosiduronate-conjugating capacity for salicylamide to normal in their patient, and by the observations of increased AER (Fig. 7) and rate of glucosiduronate conjugation of PNP (Fig. 8) (12) . 7 The turnover of phenobarbital is assumed to be rapid (51) compared to the degradation of the bilirubin-metabolizing enzyme system. This result indicates no significant difference between the mean slope of Fig. 1 and that of Fig. 2 . II. The time required to decrease total body bilirubin pool to half the control value assuming that the maximum phenobarbital effect on bilirubin half-life is induced immediately can be calculated in the following manner: Let N = bilirubin pool size at any time, t, then dN/dt = ktN + 33 (see Table II 33-ktN For N = 100 mg, half value of the control bilirubin pool, t = 3.5 days. However, from Fig. 1 , about 25 days were required to reduce serum bilirubin concentrations (presumably reflecting total body bilirubin pool) to halfvalue.
It, therefore, appears unreasonable to assume that bilirubin half-life was changed immediately to the value observed in the kinetic study done during phenobarbital therapy.
